Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00390039 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery

A Phase 3 study, sponsored by Javelin Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
256
Enrollment target

NCT00390039: Completed Phase 3 study, sponsored by Javelin Pharmaceuticals.

NCT00390039 is a Phase 3 study that has completed, run by Javelin Pharmaceuticals. The registered enrollment target is 256 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00390039, a Phase 3 study, has completed, sponsored by Javelin Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
256 participants
Enrollment target

Study Summary

Multiple-center, multiple-dose, randomized, double-blind, six-arm, active- and placebo-controlled study in patients with moderate to severe post-surgical pain from elective orthopedic surgery with safety observed for a total of 30 hours post first dose.

Interventions

  • DRUG Placebo
  • DRUG Intranasal Morphine
  • DRUG IV morphine
  • DRUG Intranasal morphine

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2006-05
Est. Completion 2006-09
Phase Phase 3
Javelin Pharmaceuticals

9 total trials

What the finished NCT00390039 record still lists

NCT00390039 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT00390039 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00390039 about?

NCT00390039 is a clinical study titled "Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery". Multiple-center, multiple-dose, randomized, double-blind, six-arm, active- and placebo-controlled study in patients with moderate to severe post-surgical pain from elective orthopedic surgery with safety observed for a total of 30 hours post first dose.

What is the current status of trial NCT00390039?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2006-05. Estimated completion is 2006-09.

What interventions are being tested in trial NCT00390039?

The interventions under investigation include: Placebo (DRUG), Intranasal Morphine (DRUG), IV morphine (DRUG), Intranasal morphine (DRUG).

Who is sponsoring clinical trial NCT00390039?

This trial is sponsored by Javelin Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00390039's enrollment target sits among peer trials

256 1240th of 2000 higher than 759 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02464696 · 256 participants · NA

    Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

  • NCT03793062 · 256 participants

    Genetic and Epigenetic Basis of Chronic Wounds

  • NCT04322318 · 256 participants · Phase 2

    A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • NCT04468360 · 256 participants · Phase 2

    Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00390039, the US trial registry maintained by the National Library of Medicine. NCT00390039 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.